Blue Cross Blue Shield NM Vitamin D Coverage

Coverage Criteria for Vitamin D Testing

25-hydroxyvitamin D — Medically Necessary Indications

Covered when ANY of the following clinical indications are present

25-OH testing indications

Guideline 1 — Enumerated indications: Biliary cirrhosis and other specified disorders of the biliary tract; Blind syndrome loop; Celiac disease; Coronary artery disease when considering risk of progression vs benefits of chronic vitamin D and calcium therapy; Dermatomyositis; Eating disorders; Hypercalcemia, hypocalcemia or other disorders of calcium metabolism; Hypervitaminosis of vitamin D; Hyperparathyroidism or hypoparathyroidism; Individuals receiving hyperalimentation; Liver cirrhosis; Intestinal malabsorption; Long-term use of anticonvulsants, glucocorticoids and other medications known to lower vitamin D levels; Malnutrition; Myalgia and other myositis; Myopathy related to endocrine diseases; Neoplastic hematologic disorders; Obesity; Osteogenesis imperfecta; Osteomalacia; Osteopetrosis; Osteoporosis; Pancreatic steatorrhea; Primary or miliary tuberculosis; Psoriasis; Regional enteritis; Renal, ureteral or urinary calculus (nephrolithiasis); Rickets; Sarcoidosis; Stage III-V Chronic Kidney Disease and End Stage Renal Disease.
Full enumerated list from Guideline 1 (see source).

25-hydroxyvitamin D — Monitoring and Frequency

Monitoring/Repeat testing covered when ALL of the following are met

Repeat monitoring 25-OH: Individual has documented vitamin D deficiency and testing is performed at least 12 weeks after initiation of vitamin D supplementation therapy.>= 12 weeks after initiation of supplementation

Repeat testing for monitoring should not exceed 2 testing instances per year until therapeutic goal is achieved; once therapeutic range has been reached, annual testing meets coverage criteria.

1,25-dihydroxyvitamin D — Medically Necessary Indications

Covered when ANY of the following clinical indications are present

1,25-OH testing indications

Guideline 2 — Enumerated indications: Disorders of calcium metabolism; Familial hypophosphatemia; Fanconi syndrome; Hyperparathyroidism or hypoparathyroidism; Neonatal hypocalcemia; Individuals receiving hyperalimentation; Osteogenesis imperfecta; Osteomalacia; Osteopetrosis; Primary or miliary tuberculosis; Rickets; Renal, ureteral or urinary calculus (nephrolithiasis); Sarcoidosis; Stage III-V Chronic Kidney Disease and End Stage Renal Disease.
Full enumerated list from Guideline 2 (see source).

Routine population or opportunistic screening for vitamin D deficiency using serum 25-hydroxyvitamin D testing in asymptomatic individuals or during general encounters is not reimbursable. The policy explicitly states that routine screening with serum testing in asymptomatic individuals and/or during general encounters is not reimbursable and may be denied.

Serum 1,25-dihydroxyvitamin D testing is not reimbursable when ordered for screening or routine deficiency evaluation. The policy specifies that 1,25-dihydroxyvitamin D serum testing for testing and screening of vitamin D deficiency is among tests that are not reimbursable.

The policy considers routine screening of asymptomatic individuals for vitamin D deficiency to be not medically necessary and therefore not reimbursable. Providers should not submit claims for serum vitamin D testing solely for routine screening in patients without signs, symptoms, or supporting clinical indications.

Specific Covered Indications

Specific disease states and conditions associated with deficiency or decreased bone density

Specific disease states and conditions associated with deficiency or decreased bone density (Guideline 1)

Guideline 1 — Full enumerated list: Biliary cirrhosis and other specified disorders of the biliary tract; Blind syndrome loop; Celiac disease; Coronary artery disease (when considering risk/benefit of chronic vitamin D and calcium therapy); Dermatomyositis; Eating disorders; Hypercalcemia, hypocalcemia or other disorders of calcium metabolism; Hypervitaminosis of vitamin D; Hyperparathyroidism or hypoparathyroidism; Individuals receiving hyperalimentation; Liver cirrhosis; Intestinal malabsorption; Long-term use of anticonvulsants, glucocorticoids and other medications known to lower vitamin D levels; Malnutrition; Myalgia and other myositis; Myopathy related to endocrine diseases; Neoplastic hematologic disorders; Obesity; Osteogenesis imperfecta; Osteomalacia; Osteopetrosis; Osteoporosis; Pancreatic steatorrhea; Primary or miliary tuberculosis; Psoriasis; Regional enteritis; Renal, ureteral or urinary calculus; Rickets; Sarcoidosis; Stage III-V Chronic Kidney Disease and End Stage Renal Disease.

These specific indications support reimbursement for 25-hydroxyvitamin D testing per Guideline 1.

Disorders of vitamin D metabolism — Guideline 2

Disorders of vitamin D metabolism (Guideline 2)

Testing Frequency and Monitoring Limits

25-hydroxyvitamin D — Repeat testing and frequency limits

Repeat testing intervalRepeat 25-hydroxyvitamin D testing is covered at least 12 weeks after initiation of vitamin D supplementation; monitoring testing should not exceed 2 instances per year until the therapeutic goal is achieved; once therapeutic range is reached, annual testing meets coverage criteria.

Condition for repeat testingIndividual must have documented vitamin D deficiency prior to repeat testing.

Maximum monitoring frequencyMonitoring repeat tests should not exceed 2 instances per year until therapeutic goal achieved.

Coding and Billing

Covered CPT/HCPCS Codesmixed

No codes listed

Repeat testing interval — key threshold

Minimum intervalRepeat testing should be performed at least 12 weeks after initiation of vitamin D supplementation.

Context for intervalApplies to individuals with documented vitamin D deficiency undergoing supplementation therapy.

Subsequent testing guidanceOnce therapeutic range is reached, annual testing meets coverage criteria.

Provider Actions and Billing Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Reimbursement is contingent on meeting the listed clinical indications and applicable frequency rules in this policy.

Prior authorization required before ordering: 25‑hydroxyvitamin D (total or D2/D3 fractions) and 1,25‑dihydroxyvitamin D when intended for diagnosis or monitoring per policy guidelines.
Frequency limits and indications must be met (e.g., repeat testing for monitoring limited to ≤2 tests/year until therapeutic goal; repeat deficiency testing allowed ≥12 weeks after supplementation initiation; annual testing allowed once therapeutic range achieved).

Documentation Required

Provider Documentation and Claims Submission

Providers must follow standard billing and documentation practices: submit accurate codes from HIPAA‑approved code sets and retain supporting clinical documentation. Claims are subject to review and may be adjusted or denied if documentation does not support medical necessity.

Ordering and Documentation Requirements

Billing Rule

Ordering requirements — document clinical indication and timing

Order tests only when clinical documentation supports a covered indication; providers may be asked to provide additional documentation to substantiate medical necessity.

Ensure the medical record documents the specific covered indication (see Guideline 1 for 25‑OH indications and Guideline 2 for 1,25‑OH indications).
Retain and provide documentation of timing for monitoring tests (e.g., date supplementation started to demonstrate ≥12 weeks before repeat 25‑OH).

Services Not Covered

Not covered: Routine screening for vitamin D deficiency in asymptomatic individuals and 1,25-dihydroxyvitamin D testing for screening are explicitly listed as non-reimbursable services. Claims for these indications may be denied if submitted without an appropriate covered clinical indication.

Definitions

25-hydroxyvitamin D (25-OH) — definition / key values

Test name25-hydroxyvitamin D (25-OH); includes total 25-OH and may include D2/D3 fractions as part of total analysis.

PurposeAssesses vitamin D status and supports diagnosis of deficiency in individuals with conditions associated with vitamin D deficiency or decreased bone density.

Covered indications (examples)Celiac disease, malabsorption, CKD stage III-V/ESRD, osteoporosis, rickets, osteomalacia, sarcoidosis, long-term anticonvulsant/glucocorticoid use, liver disease, obesity, nephrolithiasis, eating disorders, myopathy, neoplastic hematologic disorders, psoriasis, tuberculosis, osteogenesis imperfecta.

1,25-dihydroxyvitamin D (1,25-OH) — definition / key values

Test name1,25-dihydroxyvitamin D (1,25-OH).

Purpose

Background

25-hydroxyvitamin D (25-OH) measurement is used to assess vitamin D status and diagnose deficiency, while 1,25-dihydroxyvitamin D (1,25-OH) testing is reserved for evaluation of disorders of vitamin D metabolism. Blue Cross Blue Shield New Mexico ties reimbursement to specific clinical indications and monitoring intervals to discourage routine screening in asymptomatic individuals. The policy therefore: (1) allows reimbursement for 25-OH testing when underlying diseases or conditions associated with vitamin D deficiency or decreased bone density are present; (2) allows repeat 25-OH testing for documented deficiency performed at least 12 weeks after initiation of supplementation, with monitoring not to exceed 2 instances per year until therapeutic goal is reached and annual testing thereafter; and (3) limits 1,25-OH testing to evaluation or treatment of conditions associated with defects in vitamin D metabolism. Routine screening and 1,25-OH testing for screening purposes are not covered.

OpenPayer

Vitamin D laboratory testing coverage (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D)